<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83776">
  <stage>Registered</stage>
  <submitdate>31/03/2009</submitdate>
  <approvaldate>21/05/2009</approvaldate>
  <actrnumber>ACTRN12609000322235</actrnumber>
  <trial_identification>
    <studytitle>The use of advanced organ imaging in radiotherapy of the upper-abdomen for kidney response assessment and treatment optimisation</studytitle>
    <scientifictitle>In radiotherapy treatment of upper-abdominal cancer patients, can response assessment with functional single photon emission computed tomography (SPECT) imaging be used to reduce kidney toxicity and improve the radiotherapy?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Pancreatic cancer</healthcondition>
    <healthcondition>Stomach cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Pancreatic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>External beam radiotherapy for pancreatic or stomach cancer to 54 Gy in 30 daily (excluding weekends) fractions. Sequential SPECT imaging with 99m-Technetium-dimercaptosuccinic acid (99Tc-DMSA) at commencement of radiotherapy (0 weeks) and at 4, 12, 26, 52 and 78 weeks</interventions>
    <comparator>No comparator</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Observed change in regional kidney function as indicated by SPECT signal</outcome>
      <timepoint>Baseline, 4 weeks, 12 weeks, 26 weeks, 52 weeks, 78 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in glomerular filtration rate (GFR) measured via serum creatinine in blood analysis</outcome>
      <timepoint>Baseline, 4 weeks, 12 weeks, 26 weeks, 52 weeks, 78 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Urea and electrolyte levels assessed via blood analysis</outcome>
      <timepoint>Baseline, 4 weeks, 12 weeks, 26 weeks, 52 weeks, 78 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patient has histologically/cytologically proven adenocarcinoma of the pancreas or upper-gastrointestinal (GI) tract. Metastatic disease status excluded on whole body computed tomography (CT) series.
Locoregional staging of primary disease has been undertaken with dual phase (arterial and portal) spiral CT.
Adequate bone marrow function: Haemoglobin (Hb)&gt;10, White Blood Cells (WBC)&gt;3.5 (Neutrophilis&gt;1.5), Platelets &gt;100
Serum creatinine &lt;150
Patient has given written informed consent.
Performance status is East Coast Oncology Group (ECOG) grade 0, 1 or 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Major co-morbid illnesses that, in the opinion of the investigator, would jeopardise the likely completion of the treatment program.
Patients with significant loss of bodyweight (&gt;15% weight loss since diagnosis).
Treatment with any previous cytotoxic chemotherapy for the malignancy.
Previous abdominal radiotherapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>6009</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sir Charles Gairdner Hospital</primarysponsorname>
    <primarysponsoraddress>Hospital Ave
Nedlands
Western Australia 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Sir Charles Gairdner Hospital</fundingname>
      <fundingaddress>Hospital Ave
Nedlands
Western Australia 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress>N/A</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Radiotherapy to the upper-abdomen is challenging due to the presence of the kidneys. We will couple single photon emission computed tomography (SPECT) with X-ray computed tomography (CT) to determine the effect of radiotherapy on kidney function. Combining the imaging with information on delivered radiation dose will enable us to examine the complex interactions between radiation and kidney response in order to develop unique models for optimizing radiation dose delivery and predicting outcomes.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Hospital Ave
Nedlands
Western Australia 6009</ethicaddress>
      <ethicapprovaldate>8/12/2008</ethicapprovaldate>
      <hrec>2001-152</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Martin Ebert</name>
      <address>Department of Radiation Oncology
Sir Charles Gairdner Hospital
Hospital Ave
Nedlands WA 6009</address>
      <phone>+61 8 9346 4900</phone>
      <fax />
      <email>Martin.Ebert@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Martin Ebert</name>
      <address>Department of Radiation Oncology
Sir Charles Gairdner Hospital
Hospital Ave
Nedlands WA 6009</address>
      <phone>+61 8 9346 4900</phone>
      <fax />
      <email>Martin.Ebert@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Martin Ebert</name>
      <address>Department of Radiation Oncology
Sir Charles Gairdner Hospital
Hospital Ave
Nedlands WA 6009</address>
      <phone>+61 8 9346 4900</phone>
      <fax />
      <email>Martin.Ebert@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>